INTELLIA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.14 USD | +6.65% |
|
+1.37% | -27.42% |
| Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
| Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bearish | Bearish | Bearish |
| Resistance | 23.82 | 26.08 | 32.66 |
| Spread/Res. | -7.09% | -15.15% | -32.24% |
| Spread/Supp. | +10.54% | +10.54% | +22.13% |
| Support | 20.02 | 20.02 | 18.12 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- NTLA Stock
- Charts Intellia Therapeutics, Inc.
